文献速递消化与肝胆胰病理细胞病理与分子病理

无KRAS突变的黏液性胰腺囊肿中罕见BRAF突变激活RAS通路

Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation.
PubMed 文献 · Mod Pathol · 2020-08-13

该研究对108例胰腺囊性病变的囊液进行48基因NGS检测,并与CEA和细胞学比较。在31例有手术病理的病例中,NGS诊断黏液性胰腺囊性病变的敏感性88.5%、特异性100%、准确率90.3%。在GNAS阳性/KRAS阴性的IPMN中发现了罕见的非V600E外显子11/15热点BRAF突变,提示RAS通路的替代激活机制。

要点

  • NGS检测KRAS/GNAS突变诊断黏液性PCL的准确率高于CEA和细胞学。
  • 多发性KRAS突变与影像学多灶性囊肿相关。
  • GNAS阳性/KRAS阴性IPMN中可见罕见BRAF突变,提示RAS通路替代激活。

核心结论

  • NGS检测KRAS和/或GNAS突变对黏液性PCL的诊断准确性高于CEA和细胞学检查。

研究设计与样本

  • 对108例胰腺囊性病变的囊液进行48基因NGS检测,这些病例同时有CEA和/或细胞学分析。
  • 其中31例有手术组织病理结果可用于诊断准确性评估。

主要发现

  • 68例经多模态诊断的黏液性PCL中,59例(86.8%)检出KRAS和/或GNAS突变。
  • 31例有手术病理的病例中,NGS诊断黏液性PCL的敏感性88.5%、特异性100%、准确率90.3%。
  • 62例中仅29例(46.8%)细胞学见黏液/非典型 findings,58例中33例(56.9%)囊液CEA升高。
  • 7例检出不同变异等位基因频率的多重KRAS突变,其中6例影像学显示至少两个独立PCL。
  • 10例GNAS阳性/KRAS阴性病例中,6例检出罕见的非V600E外显子11/15热点BRAF突变。

关键数值与推荐

  • 囊液CEA阈值≥192 ng/ml用于鉴别黏液性与良性PCL。
  • NGS panel包含GNAS、KRAS、CDKN2A、TP53等黏液性PCL常见突变基因。

临床怎么用

  • 对胰腺囊液进行NGS检测KRAS/GNAS突变可提高黏液性PCL的诊断准确性。
  • 影像学多灶性囊肿病例中,多重KRAS突变结果可辅助识别多克隆模式。
  • KRAS阴性而GNAS阳性的IPMN病例,应关注罕见BRAF突变提示的RAS通路激活。

局限性

  • 仅31例有手术组织病理结果,诊断准确性评估样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diagnostic testing of pancreatic cyst fluid obtained by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has traditionally utilized elevated carcinoembryonic antigen (CEA) (≥192 ng/ml) and cytomorphologic examination to differentiate premalignant mucinous from benign pancreatic cystic lesions (PCLs). Molecular testing for KRAS/GNAS mutations has been shown to improve accuracy of detecting mucinous PCLs. Using a targeted next-generation sequencing (NGS) panel, we assess the status of PCL-associated mutations to improve understanding of the key diagnostic variables. Molecular analysis of cyst fluid was performed on 108 PCLs that had concurrent CEA and/or cytological analysis. A 48-gene NGS assay was utilized, which included genes commonly mutated in mucinous PCLs such as GNAS, KRAS, CDKN2A, and TP53. KRAS and/or GNAS mutations were seen in 59 of 68 (86.8%) cases with multimodality diagnosis of a mucinous PCL. Among 31 patients where surgical histopathology was available, the sensitivity, specificity, and diagnostic accuracy of NGS for the diagnosis of mucinous PCL was 88.5%, 100%, and 90.3%, respectively. Cytology with mucinous/atypical findings were found in only 29 of 62 cases (46.8%), with fluid CEA elevated in 33 of 58 cases (56.9%). Multiple KRAS mutations at different variant allele frequencies were seen in seven cases favoring multiclonal patterns, with six of them showing at least two separate PCLs by imaging. Among the 6 of 10 cases with GNAS + /KRAS- results, uncommon, non-V600E exon 11/15 hotspot BRAF mutations were identified. The expected high degree of accuracy of NGS detection of KRAS and/or GNAS mutations for mucinous-PCLs, as compared with CEA and cytological examination, was demonstrated. Multiple KRAS mutations correlated with multifocal cysts demonstrated by radiology. In IPMNs that lacked KRAS mutations, the concurring BRAF mutations with GNAS mutations supports an alternate mechanism of activation in the Ras pathway.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Ren R, Krishna SG, Chen W, et al. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. Mod Pathol. 2020. PMID: 32792597. doi:10.1038/s41379-020-00647-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。